These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
100 related items for PubMed ID: 16845259
1. Confocal assessment of the effects of fourth-generation fluoroquinolones on the cornea. Ly LT, Cavanagh HD, Petroll WM. Eye Contact Lens; 2006 Jul; 32(4):161-5. PubMed ID: 16845259 [Abstract] [Full Text] [Related]
2. Safety of moxifloxacin as shown in animal and in vitro studies. McGee DH, Holt WF, Kastner PR, Rice RL. Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310 [Abstract] [Full Text] [Related]
3. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. Price MO, Price FW, Maclellan D. J Cataract Refract Surg; 2005 Nov; 31(11):2137-41. PubMed ID: 16412928 [Abstract] [Full Text] [Related]
4. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. Donnenfeld E, Perry HD, Chruscicki DA, Bitterman A, Cohn S, Solomon R. Curr Med Res Opin; 2004 Nov; 20(11):1753-8. PubMed ID: 15537475 [Abstract] [Full Text] [Related]
13. Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model. Barequet IS, Habot-Wilner Z, Lavinsky F, Ziv H, Belkin M, Rosner M. Cornea; 2007 Jun; 26(5):606-9. PubMed ID: 17525660 [Abstract] [Full Text] [Related]
15. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841 [Abstract] [Full Text] [Related]